MPM Capital and Qiming Venture Partners USA have co-led a series A round for Umoja Biopharma, based on research at Purdue University and Seattle Children’s Research Institute.
Umoja Biopharma, a US-based in-vivo immunotherapy platform developer exploiting research from Purdue University and Seattle Children’s Research Institute, launched with a $53m series A round on Wednesday co-led by MPM Capital and Qiming Venture Partners USA.
Founded in early 2019, Umoja is working on an integrated in-vivo immunotherapy platform targeting blood cancers and solid tumours, aiming to deliver its treatments with a simplicity and cost efficiency that enable widespread use.
Umoja advances work led by Philip Low, the…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
